Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.

ABSTRACT:

Introduction

Recent classification of neuroendocrine neoplasms has defined well-differentiated high-grade neuroendocrine tumors (NET G3) as a distinct entity from poorly differentiated neuroendocrine carcinoma. The optimal treatment for NET G3 has not been well-described. This study aimed to evaluate metastatic NET G3 response to different treatment regimens.

Materials and methods

This was a retrospective study of patients with NET G3 within the Mayo Clinic database. Patients' demographics along with treatment characteristics, responses, and survival were assessed. Primary endpoints were progression-free survival (PFS) and overall survival. Secondary endpoints were objective response rate (ORR) and disease control rate (DCR).

Results

Treatment data was available in 30

SUBMITTER: Liu AJ 

PROVIDER: S-EPMC8100548 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature